SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy
BiotechTV - News
00:00
KV7 epilepsy program safety and upcoming efficacy data
Vlad outlines KV7.2/3 activation benefits, a clean safety profile, and upcoming open-label efficacy results preceding the placebo-controlled trial.
Play episode from 09:14
Transcript
